[1] Pouton CW. Formulation of poorly water-soluble drugs for oral administration:Physicochemical and physiological issues and the lipid formulation classification system[J]. Eur J Pharm Sci, 2006, 29(3-4):278-287.
[2] Porter CJ, Pouton CW, Cuine JF, et al. Enhancing intestinal drug solubilisation using lipid-based delivery systems[J]. Adv Drug Deliv Rev, 2008, 60(6):673-691.
[3] Pouton CW. Lipid formulations for oral administration of drugs:non-emulsifying, self-emulsifying and self-microemulsifying' drug delivery systems[J]. Eur J Pharm Sci, 2000, 11(Suppl 2):S93-98.
[4] Carri re F. Impact of gastrointestinal lipolysis on oral lipid-based formulations and bioavailability of lipophilic drugs[J]. Biochimie. 2016, 125:297-305.
[5] Kalantzi L, Persson E, Polentarutti B, et al. Canine intestinal contents vs. simulated media for the assessment of solubility of two weak bases in the human small intestinal contents[J]. Pharm Res, 2006, 23(6):1373-1381.
[6] van Tilbeurgh H, Sarda L, Verger R, et al. Structure of the pancreatic lipase-procolipase complex[J]. Nature, 1992, 359(6391):159-162.
[7] Lowe ME. The triglyceride lipases of the pancreas[J]. J Lipid Res, 2002, 43(12):2007-2016.
[8] Shiau YF. Mechanisms of intestinal fat absorption[J]. Am J Physiol, 1981, 240(1):G1-G9.
[9] Nordskog BK, Phan CT, Nutting DF, et al. An examination of the factors affecting intestinal lymphatic transport of dietary lipids[J]. Adv Drug Deliv Rev, 2001, 50(1-2):21-44.
[10] Mattson FH, Benedict JH, Martin JB, et al. Intermediates formed during the digestion of triglycerides[J]. J Nutr, 1952, 48(3):335-344.
[11] Naylor LJ, Bakatselou V, Dressman JB. Comparison of the mechanism of dissolution of hydrocortisone in simple and mixed micelle systems[J]. Pharm Res, 1993, 10(6):865-870.
[12] Humberstone AJ, Porter CJ, Charman WN. A physicochemical basis for the effect of food on the absolute oral bioavailability of halofantrine[J]. J Pharm Sci, 1996, 85(5):525-529.
[13] Mu H, Hoy CE. The digestion of dietary triacylglycerols[J]. Prog Lipid Res, 2004, 43(2):105-133.
[14] Zangenberg NH, Mullertz A, Kristensen HG, et al. A dynamic in vitro lipolysis model.Ⅱ:evaluation of the model[J]. Eur J Pharm Sci, 2001, 14(3):237-244.
[15] Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations:Optimizing the oral delivery of lipophilic drugs[J]. Nat Rev Drug Discov, 2007, 6(3):231-248.
[16] Fatouros DG, Müllertz A. In vitro lipid digestion models in design of drug delivery systems for enhancing oral bioavailability[J]. Expert Opin Drug Metab Toxicol, 2008, 4(1):65-76.
[17] 曾棋平, 张晶, 刘志宏, 等. 脂解模型在脂质给药系统体外评价中的应用研究进展[J]. 药学实践杂志, 2014, 32(2):85-87.
[18] Dening TJ, Rao S, Thomas N, et al. Montmorillonite-lipid hybrid carriers for ionizable and neutral poorly water-soluble drugs:Formulation, characterization and in vitro lipolysis studies[J]. Int J Pharm, 2017, 526(1):95-105.
[19] Kazi M, Al-Qarni H, Alanazi FK. Development of oral solid self-emulsifying lipid formulations of risperidone with improved in vitro dissolution and digestion[J]. Eur J Pharm Biopharm, 2017, 114:239-249.
[20] 林婉婷, 龙晓英, 吴慧仪, 等. 灰黄霉素纳米乳体外脂解过程中药物动态分布研究[J]. 中国药学杂志, 2015, 50(6):512-520.
[21] Xiao L, Yi T, Liu Y, et al. The in vitro lipolysis of lipid-based drug delivery systems:A newly identified relationship between drug release and liquid crystalline phase[J]. Biomed Res Int, 2016,2016:2364317.
[22] Siqueira SD, M llertz A, Gr eser K, et al. Influence of drug load and physical form of cinnarizine in new SNEDDS dosing regimens:in vivo and in vitro evaluations[J]. AAPS J. 2017, 19(2):587-594.
[23] Tanaka Y, Hara T, Waki R, et al. Regional differences in the components of luminal water from rat gastrointestinal tract and comparison with other species[J]. J Pharm Pharm Sci, 2012, 15(4):510-518.
[24] Fatouros DG, Bergenstahl B, Mullertz A. Morphological observations on a lipid-based drug delivery system during in vitro digestion[J]. Eur J Pharm Sci, 2007, 31(2):85-94.
[25] Roshan GD, Aagaard AE, Pedersen JS, et al. Experimental Set-up with flow-through cell with SAXS studies of in-situ degradation of drug formulations under gastro-intestinal mimicking conditions[R]. 13th International Conference of Small Angle Scattering, Kyoto:2006.
[26] Sassene PJ, Knopp MM, Hesselkilde JZ, et al. Precipitation of a poorly soluble model drug during in vitro lipolysis:characterization and dissolution of the precipitate[J]. J Pharm Sci, 2010, 99(12):4982-4991.
[27] Fernandez S, Jannin V, Chevrier S, et al. In vitro digestion of the self-emulsifying lipid excipient Labrasol by gastrointestinal lipases and influence of its colloidal structure on lipolysis rate[J]. Pharm Res, 2013, 30(12):3077-3087.